Sorry the MMR safety studies/trials not record- has been criticised by the Cochrane report.
Anyway for people who can't be bothered to read the whole link I gave interesting though it is, here's the relevant bit about single vs combined. Interesting that you get a higher dose of mumps vaccine with the MMR vs singles.
5.2 Are single vaccines any less effective than the triple vaccine ?
There have been no recent comparative trials of monovalent versus combined vaccines of which I am aware. The best method by which such comparison could be carried out currently would be through case-control study in countries which have relatively low levels of MMR use and have comparison populations who are in receipt of monovalent vaccines.
The earlier studies of single vaccines show equivalent levels of seroconversion when compared to combined vaccine:
Measles:
Vaccine
Total No.
Seroconversion
Edmonson B
258
99%
Schwartz
250
98%
Moraten
273
98%
(data from Hilleman et al 1968)
Mumps:
Vaccine
Total No.
Seroconversion
Jeryl Lynn
174
95.2%
Rubella:
Vaccine
Total No.
Seroconversion
RA27/3
67
100%
(data from Weibel et al 1980)
top of page
In addition, rates of fever and rash are reported in early trial;s as being higher with the combined vaccine than with monovalent measles alone:
Comparative:
Vaccine
Total No.
Fever (>39.4°)
Rash
Measles (Moraten)
43
5%
12%
MMR (RA27/3)
141
11%
20%
MMR (HPV-77;DE-5)
142
8%
17%
Placebo
42
0%
9%
(data from Lerman, Bollinger & Brunken 1981)
A large number of comparative trials were carried out (the Committee is referred to IABS 1986 for an introduction to this area).
As far as I can ascertain, all of the earlier studies were used to justify the view that trivalent MMR vaccines were equally efficacious to and not better monovalent vaccines.
The principal justification used for their introduction at the time would seem to have been financial -
The benefit to cost ratio from introduction of MMR vaccines as opposed to monovalent vaccines in the USA was estimated as changing from 11.9 to 1 to 14 to 1 (White, Coplan & Orenstein 1985), with an estimated saving to the healthcare budget of some $60 million per annum (Markowitz & Katz 1994).
One important difference in the constitution of the trivalent as opposed to monovalent vaccines was the finding that simultaneous administration resulted in substantially reduced seroconversion for mumps though not for measles or rubella (see: Andre & Peetermans 1986; Berger, Just & Gluck 1988), as a consequence of which the number of viable mumps viruses in the trivalent preparation was increased (Gluck & Just 1991).